Caliway Is Dedicated To Pioneering Small Molecule Medications Catering To Aesthetics And Various Diseasestapping Into A Burgeoning Market Valued At Over $10 Billionour Flagship Compoundcbl 514Showcased Remarkable Efficacy In Phase 2 Clinical Trialsnotably Reducing Subcutaneous Fat By An Average Of 312Ml In Treated Areas While Also Demonstrating Promising Improvements In Cellulite Without Significant Systemic Side Effectsfurthermoreour Pipeline Boasts Cbl 514Dearmarked For Addressing Dercum S Diseasea Rare Condition Characterized By Painful Lipoma Growthsfor More Informationplease Visitcaliway Com Tw En
